Cardiotoxicity of cancer treatment.
作者信息
Shuel Sian L
机构信息
General practitioner in oncology in Abbotsford, BC, and Medical Education Lead of BC Cancer's Primary Care Program.
出版信息
Can Fam Physician. 2024 Oct;70(10):629-631. doi: 10.46747/cfp.7010629.
Abstract
摘要
相似文献
1
Cardiotoxicity of cancer treatment.癌症治疗的心脏毒性。
Can Fam Physician. 2024 Oct;70(10):629-631. doi: 10.46747/cfp.7010629.
2
[Cancer therapy-induced cardiotoxicity].[癌症治疗引起的心脏毒性]
Rev Med Liege. 2016 Sep;71(9):382-387.
3
New insights into cardiotoxicity caused by chemotherapeutic agents.新型化疗药物心脏毒性研究进展。
Br J Pharmacol. 2017 Nov;174(21):3675-3676. doi: 10.1111/bph.14025.
4
Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.化疗所致心脏毒性的多模态评估与治疗
Future Cardiol. 2015 Jul;11(4):421-4. doi: 10.2217/FCA.15.49. Epub 2015 Aug 4.
5
[Cardiotoxicity. A reality that the primary care physician should be aware].
Semergen. 2017 Mar;43(2):149-150. doi: 10.1016/j.semerg.2016.03.015. Epub 2016 Apr 23.
6
Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.改变观念：改善癌症治疗相关心脏毒性的结局。
Curr Oncol Rep. 2019 Jan 30;21(1):9. doi: 10.1007/s11912-019-0751-0.
7
Oncologic therapies associated with cardiac toxicities: how to minimize the risks.与心脏毒性相关的肿瘤治疗药物：如何将风险最小化。
Expert Rev Anticancer Ther. 2019 May;19(5):359-374. doi: 10.1080/14737140.2019.1596804. Epub 2019 Apr 10.
8
[Immune checkpoint inhibitor-related cardiotoxicities].免疫检查点抑制剂相关的心脏毒性
Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):75-77. doi: 10.3760/cma.j.issn.0578-1426.2020.01.014.
9
Onco-cardiology: Present and future.肿瘤心脏病学：现状与未来。
Int J Cardiol. 2016 Jul 15;215:38-40. doi: 10.1016/j.ijcard.2016.04.074. Epub 2016 Apr 13.
10
Advanced imaging modalities to detect cardiotoxicity.用于检测心脏毒性的先进成像方式。
Curr Probl Cancer. 2018 Jul;42(4):386-396. doi: 10.1016/j.currproblcancer.2018.05.005. Epub 2018 Jun 11.
引用本文的文献
1
Post-treatment late and long-term effects in bone sarcoma: A scoping review.骨肉瘤治疗后的晚期和长期影响：一项范围综述。
J Bone Oncol. 2025 Mar 21;52:100671. doi: 10.1016/j.jbo.2025.100671. eCollection 2025 Jun.
本文引用的文献
1
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy.血液系统恶性肿瘤新型治疗药物的心脏毒性：嵌合抗原受体 T 细胞疗法和双特异性 T 细胞衔接器疗法。
JCO Oncol Pract. 2023 Jun;19(6):331-342. doi: 10.1200/OP.22.00713. Epub 2023 Mar 17.
2
Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS).卡非佐米引起的心脏毒性：对美国食品药品监督管理局不良事件报告系统（FAERS）的分析。
J Saudi Heart Assoc. 2022 Aug 31;34(3):134-141. doi: 10.37616/2212-5043.1311. eCollection 2022.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.免疫检查点抑制剂相关的心血管免疫毒性：安全性荟萃分析。
Eur Heart J. 2021 Dec 21;42(48):4964-4977. doi: 10.1093/eurheartj/ehab618.
5
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
6
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.免疫检查点抑制剂治疗相关的心脏毒性：一项荟萃分析。
Eur J Heart Fail. 2021 Oct;23(10):1739-1747. doi: 10.1002/ejhf.2289. Epub 2021 Jul 29.
7
Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC.癌症患者的心血管风险分层与管理。西班牙心脏病学会、西班牙肿瘤学会、西班牙肿瘤放射治疗学会、西班牙血液病学会、西班牙老年病学会、西班牙心脏病学和心血管病学会、西班牙急诊医学和重症监护学会、西班牙急诊医师学会、西班牙癌症护理学会共识文件。
Rev Esp Cardiol (Engl Ed). 2021 May;74(5):438-448. doi: 10.1016/j.rec.2020.11.020. Epub 2021 Mar 10.
8
Fatal heart disease among cancer patients.癌症患者的致命心脏病。
Nat Commun. 2020 Apr 24;11(1):2011. doi: 10.1038/s41467-020-15639-5.
9
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.心血管肿瘤康复管理癌症患者和幸存者的心血管结局：美国心脏协会的科学声明。
Circulation. 2019 May 21;139(21):e997-e1012. doi: 10.1161/CIR.0000000000000679.
10
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.成人癌症幸存者心功能障碍的预防和监测：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
Zotero 插件